TMS (Transcranial Magnetic Stimulator) Market ($2.02Bn by 2028) Growth Forecast at 8.8% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by TheInsightPartners.com
August 24, 2021 15:44 ET
|
The Insight Partners
New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Transcranial Magnetic Stimulator (TMS) Market: Key InsightsAccording to our latest study on “Transcranial Magnetic Stimulator (TMS) Market Forecast to...
Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP
July 26, 2021 07:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 11, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
April 26, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
March 11, 2021 07:05 ET
|
Annovis Bio, Inc.
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
February 01, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
January 28, 2021 09:20 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company and wholly owned...
Zhittya Genesis Medicine Announces a Potential Major Medical Breakthrough for the Treatment of Parkinson’s Disease
September 22, 2020 10:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announces that it will initiate clinical trials to test a medical hypothesis that has been...
Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye
August 11, 2020 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina,...
Zhittya Genesis Medicine, Inc. Announces a Zoom Webinar
July 22, 2020 10:30 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, July 22, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announced that it will give a Zoom Webinar on its potential breakthrough therapy to reverse...